Technical Data
C7850-27B
C5b-9 Terminal Complement Complex (TCC) (Biotin)
Description:
C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and is directed against a neoepitope exposed on C9 when incorporated into the TCC.

Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilutions:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2a,k13A96Purified
SizeStorageShippingSourceHost
100ul-20°CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Purified C5b-9
Purity:
Purified
Form
Supplied as a liquid in PBS, pH 7.4, 15mM sodium azide. Labeled with Biotin.
Specificity:
Recognizes human C5b-9. Binds both membrane-bound MAC and fluid-phase SC5b-9 complexes. Species Crossreactivity: porcine, baboon, equine
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Mollnes TE, Lea T, Harboe M, Tschopp J (1985) Monoclonal antibodies recognizing a neoantigen of poly (C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol 22:183-195. 2. Drogari-Aspiranthitou M, Kuijper EJ, Dekker N, Dankert J (2002) Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity. Infect Immunol 70:3752-3758. 3. Jansen JH, Høgåsen K, Mollnes TE (1993) Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 143:1356-1365. 4. Mollnes TE, Redl H, Høgåsen K, Bengtsson A, Garred P, Speilberg L, Lea T, Oppermann M, Götze O, Schlag G (1993) Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).Clin Exp Immunol 91:295-300. 5. Mollnes TE, Lea T, Frøland SS, Harbroe M (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22:197-202. 6. Mollnes TE (1997) Analysis of in vivo complement activation. Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C: Weir's Handbook of Experimental Immunology. Boston, MA: Blackwell Science, pp. 78.1-78.8. 7. Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P (1989) Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut 30:361-6. 8. Halstensen TS, Mollnes TE, Brandtzaeg P (1989) Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology 97:10-9. 9. Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P (1990) Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 98:1264-71.